Insights
Search Results
Client Highlights
6.03.26
Wilson Sonsini Advises Isomorphic Labs on $2.1 Billion Series B Investment Round
On May 12, 2026, Isomorphic Labs, an AI-first drug design and development company, announced it has raised $2.1 billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base. Wilson Sonsini Goodrich & Rosati advised Isomorphic Labs on the transaction.
Client Highlights
5.14.26
Wilson Sonsini Advises Insider One on Acquisition of Bluecore
On May 13, 2026, Insider One, a leading agentic customer engagement platform, announced its acquisition of Bluecore, a leading retail marketing technology platform serving more than 400 U.S. enterprise brands. Terms of the transaction have not been disclosed. Wilson Sonsini Goodrich & Rosati advised Insider One on the transaction.
Client Highlights
3.02.26
Wilson Sonsini Advises Sense on Strategic Investment from Analog Devices
On January 27, 2026, Sense, a leader in grid edge intelligence, announced it has received a strategic investment from Analog Devices, Inc. (ADI), a global semiconductor leader that bridges the physical and digital worlds to enable breakthroughs at the Intelligent Edge. This new investment enables further development of grid edge intelligence and management solutions for grid operators. Together, the companies will work with smart meter developers and others in the energy industry to accelerate the adoption of high-performance data and computation capabilities to enable a smarter grid. Wilson Sonsini Goodrich & Rosati advised Sense on the transaction.
Client Highlights
11.06.25
Wilson Sonsini Advises Azalea Therapeutics on $82 Million Financing
On November 4, 2025, Azalea Therapeutics, a biotechnology company redefining precision genomic medicines in vivo, announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary Enveloped Delivery Vehicle (EDV) technology. The funding was led by Third Rock Ventures, with participation from RA Capital Management, Yosemite, Sozo Ventures, and select individual investors. Wilson Sonsini Goodrich & Rosati advised Azalea Therapeutics on the transaction.
Client Highlights
10.02.25
Wilson Sonsini Advises BeSound on $6.8 Million Financing
On September 30, 2025, BLOCH Quantum Imaging Solutions, Inc. (dba BeSound), a pioneering healthcare technology company revolutionizing breast cancer detection, announced it has raised $6.8 million from investors, including Overwater Ventures, Kindred Ventures, Muse Capital, Lux Capital, Wisdom.VC, Retron VC, Mana Ventures, Pave Health Ventures, SSC Venture Partners, Hyperplane VC, and Tom Hale, the CEO of Oura. Wilson Sonsini Goodrich & Rosati advised BeSound on the transaction.
Client Highlights
1.06.25
Wilson Sonsini Advises Clear Future on Purchase of FC2 Female Condom
On December 31, 2024, Veru Inc., a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm, as well as other co-investors subject to adjustment as set forth in the purchase agreement. Wilson Sonsini Goodrich & Rosati advised Clear Future, Inc. on the transaction.